vs

Side-by-side financial comparison of NU SKIN ENTERPRISES, INC. (NUS) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

NU SKIN ENTERPRISES, INC. is the larger business by last-quarter revenue ($370.3M vs $197.9M, roughly 1.9× REPLIGEN CORP). REPLIGEN CORP runs the higher net margin — 6.7% vs 3.9%, a 2.8% gap on every dollar of revenue. On growth, REPLIGEN CORP posted the faster year-over-year revenue change (13.6% vs -16.9%). REPLIGEN CORP produced more free cash flow last quarter ($17.6M vs $5.9M). Over the past eight quarters, REPLIGEN CORP's revenue compounded faster (14.4% CAGR vs -5.8%).

Nu Skin Enterprises, Inc. is an American multilevel marketing company that develops and sells personal care products and dietary and nutritional supplements. Under the Nu Skin and Pharmanex brands, the company sells its products in 54 markets through a network of approximately 1.2 million independent distributors.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

NUS vs RGEN — Head-to-Head

Bigger by revenue
NUS
NUS
1.9× larger
NUS
$370.3M
$197.9M
RGEN
Growing faster (revenue YoY)
RGEN
RGEN
+30.5% gap
RGEN
13.6%
-16.9%
NUS
Higher net margin
RGEN
RGEN
2.8% more per $
RGEN
6.7%
3.9%
NUS
More free cash flow
RGEN
RGEN
$11.7M more FCF
RGEN
$17.6M
$5.9M
NUS
Faster 2-yr revenue CAGR
RGEN
RGEN
Annualised
RGEN
14.4%
-5.8%
NUS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NUS
NUS
RGEN
RGEN
Revenue
$370.3M
$197.9M
Net Profit
$14.5M
$13.3M
Gross Margin
70.7%
52.5%
Operating Margin
6.3%
9.0%
Net Margin
3.9%
6.7%
Revenue YoY
-16.9%
13.6%
Net Profit YoY
140.1%
143.9%
EPS (diluted)
$0.27
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NUS
NUS
RGEN
RGEN
Q4 25
$370.3M
$197.9M
Q3 25
$364.2M
$188.8M
Q2 25
$386.1M
$182.4M
Q1 25
$364.5M
$169.2M
Q4 24
$445.6M
$174.1M
Q3 24
$430.1M
$154.9M
Q2 24
$439.1M
$154.1M
Q1 24
$417.3M
$151.3M
Net Profit
NUS
NUS
RGEN
RGEN
Q4 25
$14.5M
$13.3M
Q3 25
$17.1M
$14.9M
Q2 25
$21.1M
$14.9M
Q1 25
$107.5M
$5.8M
Q4 24
$-36.1M
$-30.3M
Q3 24
$8.3M
$-654.0K
Q2 24
$-118.3M
$3.3M
Q1 24
$-533.0K
$2.1M
Gross Margin
NUS
NUS
RGEN
RGEN
Q4 25
70.7%
52.5%
Q3 25
70.5%
53.2%
Q2 25
68.8%
50.0%
Q1 25
67.8%
53.6%
Q4 24
62.7%
26.1%
Q3 24
70.1%
50.0%
Q2 24
70.0%
49.8%
Q1 24
70.5%
49.5%
Operating Margin
NUS
NUS
RGEN
RGEN
Q4 25
6.3%
9.0%
Q3 25
5.9%
8.9%
Q2 25
8.0%
7.6%
Q1 25
-2.7%
3.9%
Q4 24
-11.9%
-17.7%
Q3 24
4.2%
-5.1%
Q2 24
-28.6%
1.0%
Q1 24
2.1%
1.3%
Net Margin
NUS
NUS
RGEN
RGEN
Q4 25
3.9%
6.7%
Q3 25
4.7%
7.9%
Q2 25
5.5%
8.2%
Q1 25
29.5%
3.4%
Q4 24
-8.1%
-17.4%
Q3 24
1.9%
-0.4%
Q2 24
-26.9%
2.2%
Q1 24
-0.1%
1.4%
EPS (diluted)
NUS
NUS
RGEN
RGEN
Q4 25
$0.27
$0.24
Q3 25
$0.34
$0.26
Q2 25
$0.43
$0.26
Q1 25
$2.14
$0.10
Q4 24
$-0.73
$-0.55
Q3 24
$0.17
$-0.01
Q2 24
$-2.38
$0.06
Q1 24
$-0.01
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NUS
NUS
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$239.8M
$767.6M
Total DebtLower is stronger
$542.2M
Stockholders' EquityBook value
$805.2M
$2.1B
Total Assets
$1.4B
$2.9B
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NUS
NUS
RGEN
RGEN
Q4 25
$239.8M
$767.6M
Q3 25
$253.0M
$748.7M
Q2 25
$265.4M
$708.9M
Q1 25
$213.6M
$697.2M
Q4 24
$198.0M
$757.4M
Q3 24
$237.8M
$784.0M
Q2 24
$232.9M
$809.1M
Q1 24
$221.2M
$780.6M
Total Debt
NUS
NUS
RGEN
RGEN
Q4 25
$542.2M
Q3 25
$537.9M
Q2 25
Q1 25
Q4 24
$525.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
NUS
NUS
RGEN
RGEN
Q4 25
$805.2M
$2.1B
Q3 25
$799.8M
$2.1B
Q2 25
$787.8M
$2.1B
Q1 25
$754.0M
$2.0B
Q4 24
$651.5M
$2.0B
Q3 24
$706.9M
$2.0B
Q2 24
$686.2M
$2.0B
Q1 24
$810.2M
$2.0B
Total Assets
NUS
NUS
RGEN
RGEN
Q4 25
$1.4B
$2.9B
Q3 25
$1.4B
$2.9B
Q2 25
$1.4B
$2.9B
Q1 25
$1.4B
$2.9B
Q4 24
$1.5B
$2.8B
Q3 24
$1.6B
$2.8B
Q2 24
$1.6B
$2.9B
Q1 24
$1.7B
$2.8B
Debt / Equity
NUS
NUS
RGEN
RGEN
Q4 25
0.26×
Q3 25
0.26×
Q2 25
Q1 25
Q4 24
0.27×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NUS
NUS
RGEN
RGEN
Operating Cash FlowLast quarter
$16.6M
$25.7M
Free Cash FlowOCF − Capex
$5.9M
$17.6M
FCF MarginFCF / Revenue
1.6%
8.9%
Capex IntensityCapex / Revenue
2.9%
4.1%
Cash ConversionOCF / Net Profit
1.15×
1.93×
TTM Free Cash FlowTrailing 4 quarters
$46.0M
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NUS
NUS
RGEN
RGEN
Q4 25
$16.6M
$25.7M
Q3 25
$27.5M
$48.1M
Q2 25
$35.8M
$28.6M
Q1 25
$389.0K
$15.0M
Q4 24
$25.8M
$39.2M
Q3 24
$31.4M
$49.3M
Q2 24
$51.2M
$42.2M
Q1 24
$3.3M
$44.7M
Free Cash Flow
NUS
NUS
RGEN
RGEN
Q4 25
$5.9M
$17.6M
Q3 25
$17.6M
$43.4M
Q2 25
$35.8M
$21.5M
Q1 25
$-13.2M
$11.4M
Q4 24
$13.2M
$33.6M
Q3 24
$22.8M
$42.3M
Q2 24
$43.1M
$37.4M
Q1 24
$-9.0M
$36.4M
FCF Margin
NUS
NUS
RGEN
RGEN
Q4 25
1.6%
8.9%
Q3 25
4.8%
23.0%
Q2 25
9.3%
11.8%
Q1 25
-3.6%
6.8%
Q4 24
3.0%
19.3%
Q3 24
5.3%
27.3%
Q2 24
9.8%
24.3%
Q1 24
-2.1%
24.0%
Capex Intensity
NUS
NUS
RGEN
RGEN
Q4 25
2.9%
4.1%
Q3 25
2.7%
2.5%
Q2 25
0.0%
3.9%
Q1 25
3.7%
2.1%
Q4 24
2.8%
3.2%
Q3 24
2.0%
4.5%
Q2 24
1.9%
3.1%
Q1 24
2.9%
5.5%
Cash Conversion
NUS
NUS
RGEN
RGEN
Q4 25
1.15×
1.93×
Q3 25
1.61×
3.23×
Q2 25
1.69×
1.92×
Q1 25
0.00×
2.57×
Q4 24
Q3 24
3.79×
Q2 24
12.70×
Q1 24
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NUS
NUS

Other$161.9M44%
Mainland China Segment$52.0M14%
Southeast Asia Pacific Segment$50.5M14%
Europe And Africa Segment$41.8M11%
Hong Kong Taiwan Segment$29.6M8%
South Korea Segment$28.4M8%
Rhyz Other Segment$6.1M2%

RGEN
RGEN

Segment breakdown not available.

Related Comparisons